| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC22A7 |
| Uniprot No | Q9Y694 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-548 aa |
| 活性数据 | MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCALPGAPANFSHQDVWLEAHLPREPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYDHSEFSSTIATESQWDLVCEQKGLNRAASTFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYVSTLVLGLASAASVSYVMFAITRTLTGSALAGFTIIVMPLELEWLDVEHRTVAGVLSSTFWTGGVMLLALVGYLIRDWRWLLLAVTLPCAPGILSLWWVPESARWLLTQGHVKEAHRYLLHCARLNGRPVCEDSFSQEAVSKVAAGERVVRRPSYLDLFRTPRLRHISLCCVVVWFGVNFSYYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVYLSVRYAGRRLTQAGTLLGTALAFGTRLLVSSDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLAPLAALLDGVWLSLPKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEEMPMKQVQN |
| 分子量 | 86.02 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC22A7(OAT2)蛋白的参考文献示例(注：以下为假设性示例，实际文献需通过学术数据库确认)：
---
1. **文献名称**：*"Functional characterization of recombinant human SLC22A7 (OAT2) in a mammalian expression system"*
**作者**：Hilgendorf C, et al.
**摘要**：本研究在HEK293细胞中成功表达了重组人SLC22A7蛋白，并验证其作为有机阴离子转运体(OAT2)的活性。实验表明，SLC22A7对环状核苷酸(如cGMP)及抗病毒药物(如替诺福韦)具有高亲和力，提示其在肝脏药物代谢中的关键作用。
2. **文献名称**：*"Structural determinants of substrate specificity in human OAT2 (SLC22A7) revealed by site-directed mutagenesis"*
**作者**：Chen EC, et al.
**摘要**：通过重组SLC22A7蛋白的定点突变分析，研究发现了跨膜结构域中两个关键氨基酸残基(Arg34和Glu45)对底物选择性的调控作用。该结果为理解OAT2的药物相互作用机制提供了结构基础。
3. **文献名称**：*"Downregulation of hepatic SLC22A7 in non-alcoholic fatty liver disease modulates drug clearance"*
**作者**：Yee SW, et al.
**摘要**：研究发现非酒精性脂肪肝(NAFLD)模型中，重组SLC22A7蛋白的表达显著下调，导致内源性代谢物(如前列腺素E2)和外源性药物(如二甲双胍)的肝脏转运能力降低，提示疾病状态对药物代谢的影响。
4. **文献名称**：*"Metabolomic profiling identifies endogenous substrates of human OAT2 (SLC22A7)"*
**作者**：Ahn SY, et al.
**摘要**：利用重组SLC22A7蛋白的体外转运实验，结合代谢组学技术，鉴定出多种新型内源性底物，包括胆汁酸衍生物和嘌呤代谢物，扩展了OAT2在生理与病理过程中的功能认知。
---
建议通过PubMed、Web of Science等平台以“SLC22A7 recombinant”“OAT2 transporter”为关键词搜索最新文献以获取准确信息。
Solute Carrier Family 22 Member 7 (SLC22A7), also known as organic anion transporter 2 (OAT2), is a membrane transport protein encoded by the *SLC22A7* gene in humans. It belongs to the SLC22 family of solute carriers, which facilitate the translocation of endogenous and exogenous organic anions across cell membranes. SLC22A7 is primarily expressed in the liver and kidneys, playing a critical role in the uptake and elimination of small-molecule organic anions, including drugs, toxins, and metabolites.
Functionally, SLC22A7 mediates the sodium-independent transport of substrates such as prostaglandins, cyclic nucleotides, antiviral agents (e.g., penciclovir), and anticancer drugs (e.g., 5-fluorouracil). Its involvement in drug pharmacokinetics highlights its clinical relevance in drug-drug interactions and interindividual variability in therapeutic responses. Structurally, it features 12 transmembrane domains typical of SLC transporters, with extracellular N-glycosylation sites and intracellular phosphorylation motifs regulating its activity.
Studies link SLC22A7 polymorphisms to altered drug efficacy and toxicity, while dysregulated expression has been observed in liver diseases and renal dysfunction. Recombinant SLC22A7 proteins are widely used in vitro to model transport mechanisms, assess hepatotoxicity, and screen drug candidates. Ongoing research explores its potential as a biomarker or therapeutic target for metabolic and inflammatory disorders.
×
